Common Antidepressant Fluvoxamine Shows Meaningful Benefit for Long COVID Fatigue in Major Trial

After 30 days on a widely available generic pill, patients sidelined by the crushing exhaustion of long COVID were nearly 50 percent more likely to report their severe fatigue had faded to mild levels. A major international clinical trial has demonstrated that fluvoxamine, a common antidepressant, significantly reduces the profound tiredness associated with the condition. The findings, published in the Annals of Internal Medicine, provide the first strong clinical evidence for a drug that targets long COVID's most debilitating symptom.[1][3]

The REVIVE-TOGETHER trial, co-led by researchers at McMaster University, enrolled 399 adults in Brazil who had been experiencing profound fatigue for at least 90 days following a COVID-19 infection. Participants were randomly assigned to take either fluvoxamine, the diabetes medication metformin, or a placebo for a period of 60 days, allowing researchers to track their daily energy levels and overall function.[1][2]

The results offer practical reassurance for patients desperate for symptom relief. By the 60-day mark, the drug had produced a sustained reduction in exhaustion, with statistical models showing a 99 percent probability that fluvoxamine outperformed the placebo in improving patients' quality of life. For those struggling to navigate basic household tasks or return to work, the data translates to a tangible restoration of capability.[1][4]

"This is an important step forward for patients who have been desperate for evidence-based options," noted Edward Mills, a professor at McMaster University and co-principal investigator of the trial. Because fluvoxamine is already a generic medication with a well-understood safety profile, it bypasses the years of regulatory hurdles required for new drugs, making it an immediate option for clinicians to consider prescribing off-label.[2][4]

Interestingly, the trial also tested metformin, which earlier studies suggested could prevent long COVID if taken during the initial viral infection. However, the data clearly showed that once long COVID fatigue is already established, metformin offers no meaningful benefit. For patients currently navigating the condition, this helps narrow down which repurposed drugs are actually worth trying and which can be safely crossed off the list.[1]

Fluvoxamine, traditionally prescribed for obsessive-compulsive disorder under the brand name Luvox, is a selective serotonin reuptake inhibitor (SSRI). Researchers suspect its benefit in long COVID comes not from its psychological effects, but from its ability to reduce inflammation and regulate immune responses by activating the sigma-1 receptor in the body. It had previously shown success in preventing hospitalization during acute COVID-19 infections.[3]

While the trial's outcome is a major win, it is important to contextualize what the drug can and cannot do. Fluvoxamine specifically improved fatigue and overall quality of life, but long COVID is a complex syndrome that can also include brain fog, joint pain, and cardiovascular issues. The medication is not a blanket cure for the entire condition, but rather a targeted tool for its most common and disruptive symptom.[2][3]

There is also honest uncertainty about how long the relief lasts. The trial tracked patients for 90 days—30 days after they stopped taking the medication—and found that while the benefits persisted, they began to slightly wane once the drug was discontinued. Patients and their doctors will need to weigh whether ongoing treatment is necessary to maintain energy levels, and further studies will clarify the optimal duration of therapy.[3]

Ultimately, the discovery that an affordable, generic pill can restore a meaningful degree of function is a vital breakthrough. It shifts the management of long COVID fatigue from purely supportive strategies, like pacing and rest, to an active, evidence-based treatment, giving patients a tangible way to reclaim their routines.[5]